Ra Pharma specializes in developing Cyclomimetics, a new drug class that combines the diversity and specificity of antibodies with the benefits of small molecules. Their peptide-like molecules are highly-stable and have chemical structures that allow them to permeate cells. Founded in 2008, Ra Pharma focuses on intracellular protein-protein interactions and other innovative approaches to address unmet medical needs.